Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Onset Therapeutics Launches HYLATOPIC™ Emollient Foam For Atopic Dermatitis
Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, announced the FDA approval and commercial launch of HYLATOPIC™ Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis.

Schizophrenia: A Genetic Basis
Schizophrenia is a severely debilitating psychiatric disease that is thought to have its roots in the development of the nervous system; however, major breakthroughs linking its genetics to diagnosis, prognosis and treatment are still unrealized. Jill Morris, PhD assistant professor of Pediatrics at Northwestern University"s Feinberg School of Medicine and a researcher in the Human Molecular Genetics Program of Children"s Memorial Research Center studies a gene that is involved in susceptibility to schizophrenia, Disc1 (Disrupted-In-Schizophrenia 1). Two recent publications by Morris and colleagues focus on the role of Disc1 in development, particularly the migration of cells to their proper location in the brain and subsequent differentiation into their intended fate. During development, cells need to properly migrate to their final destination in order to develop into the appropriate cell-type, integrate into the corresponding network of cells and function properly. Disruption of cell migration can lead to inappropriate cell development and function, resulting in disease.
News of the day
Medtronic's Corevalve Shows Subclavian Access Success In Patients Contraindicated For Femoral Approach
Medtronic, Inc. (NYSE: MDT) announced new data
Cardiovascular

Genistein Targets MEK4 In Human Prostate Cancer Cells

Researchers have identified MEK4 as a pro-invasion protein and the target for genistein, a dietary compound, in prostate cancer cells, according to a new study published online July 28 in the Journal of the National Cancer Institute. Li Xu, M.D., Ph.D., and Raymond C. Bergan, M.D., of the Department of Medicine at Northwestern University in Chicago, and colleagues investigated the target for genistein in prostate cancer cells by assessing cell invasion and gene and protein expression of mitogen-activated protein kinase 4 (MEK4) and matrix metalloproteinase-2 (MMP-2), which is associated with cell invasion. Overexpression of MEK4 increased MMP-2 expression and cell invasion in prostate cancer cells; decreased MEK4 expression had the opposite effect. Computer modeling showed that genistein could bind to the active site of MEK4, and an enzymatic assay showed that genistein inhibited MEK4 kinase activity. The MMP-2 transcript level was statistically significantly higher in normal prostate epithelial cells, which are target cells for chemoprevention, from untreated patients with prostate cancer than from genistein-treated patients. "Thus, we have shown that it is possible to target motility-associated processes with genistein in patients with prostate cancer, have identified MEK4 as the therapeutic target for genistein in all six prostate cell lines examined, and have provided a possible mechanism to link high dietary consumption of genistein-containing foods with lower rates of prostate cancer metastasis and mortality," the authors write. Steve Graff Journal of the National Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009